€6.7M Funding for France’s First Medical Cannabis Medicines by Overseed
A New Era for Medical Cannabis in France
At the cusp of a significant shift, Overseed, a notable French biotech firm, is making waves by securing a €6.7 million fund to pioneer the production of 100% medical cannabis medicines in France. As the nation gears up to legalize the medical use of cannabis with comprehensive health insurance coverage by January 2025, Overseed positions itself as a key player. The company’s impressive fundraising efforts, including a prior €2.5 million seed round, underscore the growing acceptance and support for medical cannabis.
Backing and Partnerships Strengthens Overseed’s Mission
The injection of capital from various reputable investors, including Anthony Bourbon’s Blast.Club and the Centre-Val de Loire region’s seed fund, reflects a solid vote of confidence in Overseed’s innovative ventures. Beyond financial support, these partnerships herald a collaborative effort to advance agronomic research and mold the future of cannabis-based medicines. Since its inception in 2021, Overseed has led the pack, marked by its substantial research and development authorizations and strategic collaborations aimed at enhancing pharmaceutical-quality cannabis production.
Advancements in Research and Development
Overseed’s foundation is built on its robust research program, partnerships for active ingredient extraction and formulation, and its pioneering initiative in the medical cannabis sector. Collaborations with Stanipharm and the Pharm&Beauty group, along with joint efforts with the CNRS/CBM and the University Hospital of Orléans for preclinical and clinical studies, mark a significant advancement in developing effective, high-quality cannabis-based medicines.
Setting the Stage for Market Introduction
With a vision to introduce a selection of oral cannabis-based products, Overseed is on the brink of transforming the French pharmaceutical landscape, promising to offer “Best in Class” products. The company’s strategic push for a 100% French industry not only aims to secure national sovereignty over medical cannabis but also to ensure a reliable supply chain for patients in need.
CEO Hugés Péribère’s outlook encapsulates the spirit of innovation and readiness that Overseed brings to the French market. This readiness, backed by a wealth of manufacturing expertise, positions the company favorably as it navigates towards market entry, setting a precedent for the quality and accessibility of medical cannabis in France and potentially, across Europe.